A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the
last decade, and in many places the demand largely surpasses the capacities of the treatment
centers. Treatment of the disease remains unsatisfactory. All currently used drugs must be
administered parenterally, treatment is lengthy, and adverse drug reactions frequent. There
are currently no drugs which might be used as a tool to support disease control that is
easily administered and has low toxicity.
This study aims to assess the efficacy of DB289, a new, oral drug for treatment of first
stage sleeping sickness. The project will be executed in the framework of an international
consortium consisting of more than a dozen partners from academia, industry, and the
Ministries of Health of Angola and the Democratic Republic of Congo.